Mode
Text Size
Log in / Sign up

Cystoid Macular Edema

Part of Age-Related Macular Degeneration

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cystoid Macular Edema

6 trials tracked for Cystoid Macular Edema: 4 in phase 3 or 4.

6Trials tracked
4Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 3 Phase 3 1 Other / NA 2
  1. Phase 4 Cool vs Room-temperature Artificial Tears Completed
  2. Phase 4 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed
  3. Phase 4 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Completed
  4. Phase 3 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed
  5. N/A Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema Completed
  6. N/A Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Age-Related Macular Degeneration

Related studies from across the Age-Related Macular Degeneration family.

Stereotactic radiotherapy combined with ranibizumab for neovascular age-related macular degeneration shows potential cost benefits
Oncology RCT
Stereotactic radiotherapy combined with ranibizumab for neovascular age-related macular degeneration shows potential cost benefits Radiotherapy Shows Potential Cost Savings for Macular Degeneration Patients
Researchers evaluated the impact of stereotactic radiotherapy alongside ranibizumab for patients with neovascular age-related macular degene…
A trial suggests that adding stereotactic radiotherapy to standard care may lower healthcare costs and help track quality of life in macular…
Photobiomodulation protocol aims to consolidate preclinical evidence for ophthalmic diseases
Rheumatology Meta-analysis
Photobiomodulation protocol aims to consolidate preclinical evidence for ophthalmic diseases Planning to Review Light Therapy for Common Eye Diseases and Injuries
This is a protocol for a systematic review and meta-analysis, not a completed study. It outlines plans to evaluate photobiomodulation (PBM) …
Experts are planning a large review to see if light therapy can help treat common eye problems like glaucoma and vision loss.
Marine compounds from Mexican Pacific Sargassum may protect against AMD progression in preclinical models
Nutrition & Obesity Medicine Sys. Review
Marine compounds from Mexican Pacific Sargassum may protect against AMD progression in preclinical models Marine compounds from seaweed may protect eyes from age-related degeneration
This narrative review examines marine-derived bioactive compounds from Mexican Pacific Sargassum, including fucoxanthin, fucoidans, phlorota…
Scientists are exploring how specific compounds found in Mexican Pacific seaweed could slow the progression of age-related macular degenerat…
Central 2.50-mm geographic atrophy extent correlates with visual function measures in age-related macular degeneration
Ophthalmology RCT
Central 2.50-mm geographic atrophy extent correlates with visual function measures in age-related macular degeneration Central vision loss impacts daily life for geographic atrophy patients
This observational analysis of Phase III clinical trial data involved 856 individuals aged 50 years or more with bilateral geographic atroph…
New analysis shows that damage in the very center of the eye most affects how people with geographic atrophy experience their daily lives.
Gene therapy significantly reduces central subfield thickness in neovascular age-related macular degeneration
Ophthalmology Meta-analysis
Gene therapy significantly reduces central subfield thickness in neovascular age-related macular degeneration Gene Therapy Shows Potential to Reduce Swelling in Macular Degeneration
This meta-analysis of early-phase trials evaluates gene therapy for neovascular age-related macular degeneration. While a significant anatom…
New gene therapy research shows significant reduction in retinal swelling for patients with neovascular age-related macular degeneration.
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity
Ophthalmology Meta-analysis
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity Faricimab shows better vision outcomes for age related macular degeneration
This meta-analysis of 8 studies involving 8458 study populations found that faricimab 6 mg every sixteen weeks showed superior effects on be…
A new treatment option for age related macular degeneration may offer better vision and thinner retinal tissue than current standard drugs.
Ranibizumab and bevacizumab show comparable short-term efficacy for macular edema in retinal vein occlusion
Oncology Meta-analysis
Ranibizumab and bevacizumab show comparable short-term efficacy for macular edema in retinal vein occlusion Eye Drug Comparison Shows Similar Vision Gains
This meta-analysis of 759 patients with RVO-ME found no significant difference between intravitreal ranibizumab and bevacizumab monotherapy …
Two common eye injections work equally well for swelling caused by retinal vein blockage, a new analysis finds.
CFH Y402H and ARMS2 A69S polymorphisms are associated with increased risk of age-related macular degeneration
Ophthalmology Meta-analysis
CFH Y402H and ARMS2 A69S polymorphisms are associated with increased risk of age-related macular degeneration Specific genes linked to higher risk of age related macular degeneration
This meta-analysis evaluates the association between specific genetic polymorphisms and age-related macular degeneration (AMD) risk. The ana…
New research identifies two specific genetic variations that significantly increase the risk of developing age-related macular degeneration.
Aflibercept 8 mg at extended intervals yields comparable outcomes to 2 mg regardless of severity
Ophthalmology RCT
Aflibercept 8 mg at extended intervals yields comparable outcomes to 2 mg regardless of severity Higher doses of aflibercept show similar results for macular degeneration
This post hoc descriptive subgroup analysis of a randomized controlled trial involving 869 treatment-naže patients with neovascular age-rela…
A higher dose of aflibercept may offer the same vision benefits as lower doses for patients with neovascular age-related macular degeneratio…
Anti-VEGF plus corticosteroids improves BCVA and reduces edema recurrence in BRVO and CRVO
Ophthalmology Meta-analysis
Anti-VEGF plus corticosteroids improves BCVA and reduces edema recurrence in BRVO and CRVO Combination therapy improves vision for patients with retinal vein occlusion
This meta-analysis of 2040 patients found that anti-VEGF plus corticosteroid combination therapy resulted in better BCVA (MD -0.09) and redu…
Adding corticosteroids to anti-VEGF injections can improve vision and reduce the need for frequent eye injections in certain retinal conditi…
Migraine patients may have an increased risk of neovascular age-related macular degeneration
Neurology Sys. Review
Migraine patients may have an increased risk of neovascular age-related macular degeneration Migraine patients may face higher risk of certain eye conditions
This narrative review examines the association between migraine and various retinal conditions, including retinal migraine and AMD. The auth…
New research highlights a link between migraines and age-related macular degeneration, potentially impacting long-term vision for many suffe…
One-off 16 Gray stereotactic radiotherapy reduces anti-VEGF injections but results in worse visual acuity
Oncology RCT
One-off 16 Gray stereotactic radiotherapy reduces anti-VEGF injections but results in worse visual acuity Radiation for wet AMD cuts injections but harms vision
This randomized controlled trial of 411 patients with neovascular age-related macular degeneration found that one-off 16 Gray stereotactic r…
A single dose of radiation reduced the number of eye injections needed for wet AMD, but patients ended up with worse vision after four years…